**Immunoglobulin Treatment of Immunodeficient Patients**

Yıldız Camcıoğlu

88 Immunodeficiency

*857.* 

[10] Ferlazzo G., A. Wesa, Wie. Wie, and A. Galy. 1999. Dendritic Cells generated either from D34+ progenitor cells or from monocytes differ in their ability to activate antigen-

[11] Banchereau J, AK Palucka, M Dhodapkar, S Burkeholder, N Taquet, A Rolland, S Taquet, S Coquery, KM Wittkowski, N Bhardwaj, L Pineiro, R Steinman, J Fay. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34 (+)

[12] Mackensen A., B. Herbst, J. Chen, G. Kohler, C. Noppen, W. Herr, G. Spagnoli, V. Cerundolo and A. Lindemann. 2000. Phase 1 study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic

[13] Luft T., K. Pang, E. Thomas, C. Bradley, H. Savoia, J. Trapani, and J. Cebon. 1998. A serum-free culture model for studying the differentiation of human dendritic cells from

[14] Kowalkowski K., M. Alzona, F. Aono, D. Van Epps and M. Vachula. 1998. Ex Vivo Generation of Dendritic Cells from CD34+ Cells in Gas-Permeable containers Under

[15] Mu L.J., G. Gaudernack, S. Sæbøe-Larssen, H. Hammerstad, A. Tierens, G. Kvalheim. 2003. A Protocol for Generation of Clinical Grade mRNA-Transfected Monocyte-Derived Dendritic Cells for Cancer Vaccines *Scandinavian J. Immunology* 2, 58: 578-586 [16] Blystad A.K., H. Holte, S. Kvaløy, E. Smeland, J. Delabie, G. Kvalheim. 2001. High-dose therapy in patients with Hodgkin disease: the use of selected CD34+ cells is as safe as unmanipulated peripheral progenitor cells (PBPC). *Bone marrow Transplantation. 28:849-*

[17] Sæbøe-Larssen S., E. Fossberg, G. Gaudernack. 2002. mRNA-based electrotransfection of human dendritic cells and induction of T-lymphocyte responses against the

[18] Kvalheim G. 2002. Clinical use of enriched CD34+ cells. *Blood Therapies in medicine. 2:57-64*  [19] Sallusto F., A. Lanzavecchia, 1994, Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF plus IL-4 and downregulated by TNF-

[20] Caux C., C. Dezutter-Dambuyant, D. Schmitt, J. Banchereau. 1992. GM-CSF and TNFalpha cooperate in the generation of dendritic langerhans cells. *Nature 360:258* [21] Curti A., M. Fogli, M. Ratta, S. Tura, and R.Lemoli 2001. Stem cell factor and FLT3 ligand are strictly required to sustain the long-term expansion of primitive CD34+ DR-

[22] Luft T., K. Pang, E. Thomas, P. Hertzog, D.Hart, J. Trapani, and J. Cebon 1998. Type Ι IFNs enhance the terminal differentiation of DC. *The J. Immunol. 161:1947-1953* [23] Boczkowski B., S. K. Nair, J. Nam, H. Lyerly, and E. Gilboa 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with

telomerase catalytic subunit ( hTERT). *J. Immunol. Methods*, *1:191* 

messenger RNA amplified from tumor cells. *Cancer Research 60:1028*

progenitor-derived dendritic cell vaccine. Cancer Res. 1; 61(17): 6451-6458

specific CD8+ T cells *J. Immunology, 163:3597-3604*

progenitor cells. *Int. J. Cancer, 86:385-392*

alpha. *J. Exp. Med*., 179:110919.

dendritic cell precursors. *The J. Immunol. 166:*848

adult CD34+ progenitor cells. *Exp. Hematology, 26:489-500*

Serum-Free Conditions. *J. Hematotherapy 7: 403-411*

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/51660
